Annual EBIT
-$15.47 M
+$21.90 M+58.60%
December 31, 2023
Summary
- As of February 21, 2025, APRE annual earnings before interest & taxes is -$15.47 million, with the most recent change of +$21.90 million (+58.60%) on December 31, 2023.
- During the last 3 years, APRE annual EBIT has risen by +$37.34 million (+70.70%).
- APRE annual EBIT is now -198258.97% below its all-time high of -$7800.00, reached on December 1, 2004.
Performance
APRE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$4.10 M
-$250.10 K-6.50%
September 30, 2024
Summary
- As of February 21, 2025, APRE quarterly earnings before interest & taxes is -$4.10 million, with the most recent change of -$250.10 thousand (-6.50%) on September 30, 2024.
- Over the past year, APRE quarterly EBIT has dropped by -$947.30 thousand (-30.08%).
- APRE quarterly EBIT is now -54.51% below its all-time high of -$2.65 million, reached on December 31, 2022.
Performance
APRE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$14.77 M
-$574.10 K-4.04%
September 30, 2024
Summary
- As of February 21, 2025, APRE TTM earnings before interest & taxes is -$14.77 million, with the most recent change of -$574.10 thousand (-4.04%) on September 30, 2024.
- Over the past year, APRE TTM EBIT has dropped by -$769.30 thousand (-5.50%).
- APRE TTM EBIT is now -403.92% below its all-time high of -$2.93 million, reached on September 30, 2018.
Performance
APRE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
APRE EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +58.6% | -30.1% | -5.5% |
| 3 y3 years | +70.7% | +56.6% | +66.3% |
| 5 y5 years | +6.2% | +43.2% | +50.0% |
APRE EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +58.7% | -54.5% | +81.8% | -5.5% | +69.1% |
| 5 y | 5-year | at high | +70.7% | -54.5% | +81.8% | -5.5% | +72.0% |
| alltime | all time | <-9999.0% | +70.7% | -54.5% | +81.8% | -403.9% | +72.0% |
Aprea Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.10 M(+6.5%) | -$14.77 M(+4.0%) |
| Jun 2024 | - | -$3.85 M(+22.1%) | -$14.19 M(+1.4%) |
| Mar 2024 | - | -$3.15 M(-14.3%) | -$14.00 M(-9.5%) |
| Dec 2023 | -$15.47 M(-58.6%) | -$3.67 M(+4.3%) | -$15.47 M(+7.1%) |
| Sep 2023 | - | -$3.52 M(-3.5%) | -$14.45 M(-4.5%) |
| Jun 2023 | - | -$3.65 M(-21.0%) | -$15.13 M(-55.4%) |
| Mar 2023 | - | -$4.62 M(+74.3%) | -$33.92 M(-9.2%) |
| Dec 2022 | -$37.37 M(-0.2%) | -$2.65 M(-36.9%) | -$37.37 M(-12.2%) |
| Sep 2022 | - | -$4.20 M(-81.3%) | -$42.55 M(-10.9%) |
| Jun 2022 | - | -$22.45 M(+178.0%) | -$47.78 M(+35.2%) |
| Mar 2022 | - | -$8.07 M(+3.1%) | -$35.33 M(-5.6%) |
| Dec 2021 | -$37.45 M(-29.1%) | -$7.83 M(-17.0%) | -$37.45 M(-14.6%) |
| Sep 2021 | - | -$9.43 M(-5.7%) | -$43.84 M(-6.0%) |
| Jun 2021 | - | -$10.00 M(-1.9%) | -$46.65 M(-8.8%) |
| Mar 2021 | - | -$10.19 M(-28.4%) | -$51.13 M(-3.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$52.81 M(+78.8%) | -$14.22 M(+16.3%) | -$52.81 M(+4.4%) |
| Sep 2020 | - | -$12.23 M(-15.5%) | -$50.57 M(+11.0%) |
| Jun 2020 | - | -$14.48 M(+22.0%) | -$45.55 M(+23.1%) |
| Mar 2020 | - | -$11.87 M(-0.9%) | -$37.01 M(+25.3%) |
| Dec 2019 | -$29.54 M(+79.2%) | -$11.98 M(+66.0%) | -$29.54 M(+27.3%) |
| Sep 2019 | - | -$7.22 M(+21.6%) | -$23.21 M(+22.7%) |
| Jun 2019 | - | -$5.94 M(+34.7%) | -$18.92 M(+45.8%) |
| Mar 2019 | - | -$4.41 M(-21.9%) | -$12.98 M(+51.4%) |
| Dec 2018 | -$16.49 M(+4.0%) | -$5.64 M(+92.5%) | -$8.57 M(+192.5%) |
| Sep 2018 | - | -$2.93 M | -$2.93 M |
| Dec 2017 | -$15.85 M(+400.2%) | - | - |
| Jun 2008 | -$3.17 M(-44.8%) | - | - |
| Jun 2007 | -$5.74 M(-34.3%) | - | - |
| Jun 2006 | -$8.73 M(>+9900.0%) | - | - |
| Dec 2004 | -$7800.00 | - | - |
FAQ
- What is Aprea Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Aprea Therapeutics?
- What is Aprea Therapeutics annual EBIT year-on-year change?
- What is Aprea Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Aprea Therapeutics?
- What is Aprea Therapeutics quarterly EBIT year-on-year change?
- What is Aprea Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Aprea Therapeutics?
- What is Aprea Therapeutics TTM EBIT year-on-year change?
What is Aprea Therapeutics annual earnings before interest & taxes?
The current annual EBIT of APRE is -$15.47 M
What is the all time high annual EBIT for Aprea Therapeutics?
Aprea Therapeutics all-time high annual earnings before interest & taxes is -$7800.00
What is Aprea Therapeutics annual EBIT year-on-year change?
Over the past year, APRE annual earnings before interest & taxes has changed by +$21.90 M (+58.60%)
What is Aprea Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of APRE is -$4.10 M
What is the all time high quarterly EBIT for Aprea Therapeutics?
Aprea Therapeutics all-time high quarterly earnings before interest & taxes is -$2.65 M
What is Aprea Therapeutics quarterly EBIT year-on-year change?
Over the past year, APRE quarterly earnings before interest & taxes has changed by -$947.30 K (-30.08%)
What is Aprea Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of APRE is -$14.77 M
What is the all time high TTM EBIT for Aprea Therapeutics?
Aprea Therapeutics all-time high TTM earnings before interest & taxes is -$2.93 M
What is Aprea Therapeutics TTM EBIT year-on-year change?
Over the past year, APRE TTM earnings before interest & taxes has changed by -$769.30 K (-5.50%)